Detalhe da pesquisa
1.
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Liver Int
; 43(8): 1663-1676, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183524
2.
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
J Viral Hepat
; 28(2): 410-419, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185325
3.
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Liver Int
; 41(2): 295-299, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33217778
4.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
N Engl J Med
; 370(21): 1983-92, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24795200
5.
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
J Hepatol
; 64(1): 19-28, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26321288
6.
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Lancet Infect Dis
; 19(3): 275-286, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30833068
7.
Primary peritoneal tuberculosis, a forgotten localization. Case report.
Indian J Tuberc
; 65(3): 257-259, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29933870
8.
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Medicine (Baltimore)
; 96(50): e9271, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29390377
9.
CccDNA persistence during natural evolution of chronic VHB infection.
Rom J Gastroenterol
; 14(4): 373-7, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16400354
10.
Endocrine dysfunction in sepsis: a beneficial or deleterious host response?
Germs
; 5(1): 17-25, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25763364
11.
Anti-HDV IgM as a marker of disease activity in hepatitis delta.
PLoS One
; 9(7): e101002, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25072849
12.
Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
J Gastrointestin Liver Dis
; 22(1): 27-32, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23539387
13.
Clostridium difficile Infection in Hospitalized Cirrhotic Patients with Hepatic Encephalopathy.
J Gastrointestin Liver Dis
; 25(1): 120-1, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27014765
14.
Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
J Gastrointestin Liver Dis
; 18(4): 425-31, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20076814
15.
Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment.
J Gastrointestin Liver Dis
; 15(1): 51-6, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16680233
16.
Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment.
J Gastrointestin Liver Dis
; 15(3): 249-56, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17013450
17.
HBV Chronic hepatitis during chemotherapy - an immune controlled disease.
J Gastrointestin Liver Dis
; 17(4): 445-9, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19104707